Clinic of Allergology and Immunology

The Department of Clinical Immunology and Allergology at N1 “Heratsi” University Hospital is actively engaged in clinical research. The department has demonstrated consistent involvement in both sponsor-initiated and investigator-initiated studies, contributing to the advancement of research in allergology and immunological diseases.

The department has participated in international multicenter clinical trials in collaboration with leading pharmaceutical companies, including Octapharma, Chiesi Farmaceutici, and Church & Dwight.

Capabilities/Clinical research expertise

• Patient recruitment and retention
• Clinical trial coordination and management
• Experience in multicenter international studies
• Access to a diverse patient population with a high prevalence of allergic and immunological conditions
• Support for observational and interventional research

Key Research Focus Areas

• Hereditary angioedema
• Bronchial asthma
• Allergic rhinitis
• ACE inhibitor–induced angioedema
• Drug allergies
• Urticaria
• Atopic dermatitis

 Clinical Studies (2015-2027)

• An ongoing Phase III sponsor-initiated clinical trial titled the “Study of IV Human Plasma-derived C1 Esterase Inhibitor Concentrate in Patients With Congenital C1-INH Deficiency for Treatment and Pre-procedure Preventing of Acute Hereditary Angioedema Attacks”, led by Armine Hakobyan, is being conducted between 2024 and 2027 with support from Octapharma.

• The TRECOS Asthma Study, a Phase III sponsor-initiated clinical trial led by Armine Hakobyan and sponsored by Chiesi, was conducted between 2023 and 2025.
• Another ongoing investigator-initiated observational study, Bradykinin Angioedema Biomarkers, led by Zaruhi Kalikyan, is being carried out between 2025 and 2028 and is state-funded.
• NAREG Registry (Autoimmune Diseases)is a longitudinal, prospective, multicenter Armenian registry focused on systemic autoimmune and autoinflammatory diseases, incorporating an integrated biobanking component. Within its framework, comprehensive clinical data collection and biological sample storage are conducted, including dedicated efforts for patients with hereditary angioedema, enabling advanced research and improved understanding of these conditions. The project is ongoing, the PI is Armine Hakobyan. Enrolled patients up to now 20.
• In 2022, a Phase III sponsor-initiated clinical trial titled Sterimar Allergic Rhinitis Study, led by Armine Hakobyan and sponsored by Church & Dwight, was successfully completed, enrolling 59 patients (ClinicalTrials.gov Identifier: NCT05506709).
• Previously, the department completed an investigator-initiated observational study titled Drug Allergy in Armenia, also led by Zaruhi Kalikyan, conducted between 2018 and 2020 with state funding.

Contact Person

Armine Hakobyan

Email: arminehakobyan.v@gmail.com

Study team

• Mariam Movsisyan
• Armen Grigoryan
• Meline Suqiasyan
• Angelina Abgaryan
• Zaruhi Kalikyan
• Mary Khachatryan

Publications

1. Movsisyan, M., Harutyunyan, H., Movsisyan, K., Kasparova, I., Hakobyan, A., & Yenkoyan, K. (2025). Age-related peculiarities of antibody-mediated humoral immune response following SARS-CoV-2 infection. Experimental Gerontology, 203, 112735.
2. Harutyunyan, H., Hovhannisyan, A., Torosyan, H., Hakobjanyan, G., Grigoryan, A., Petrosyan, G., Movsisyan M., … & Yenkoyan, K. B. (2024). Clinical performance and application of novel serum collection “Ser-Col” device in the practice of laboratory diagnosis of infection diseases and several other immunochemical tests. Clinica Chimica Acta, 119970.
3. Movsisyan M., Truzyan N., Kasparova I., Chopikyan A., Sawaqed R. E., Bedross A., … Hakobyan A. & Yenkoyan, K. (2024). Tracking the evolution of anti-SARS-CoV-2 antibodies and long-term humoral immunity within 2 years after COVID-19 infection. Scientific reports, 14(1), 13417.
4. Movsisyan , Chopikyan A., Kasparova I., Hakobjanyan G., Carrat F., Meline Sukiasyan, … Hakobyan A., ….& Mekinian A., Yenkoyan K. Kinetics of anti-nucleocapsid IgG response in COVID-19 immunocompetent convalescent patients. Sci Rep. 2022 Jul 20;12(1):12403. doi: 10.1038/s41598-022-16402-0.
5. Movsisyan M., Chopikyan A., Kasparova I., Hakobjanyan G., Carrat F., Mekinian A., Sukiasya. M., Rushanyan M, Chalabyan M., Shariff S., Kantawala B, Hakobyan A., Petrosyan G., Yenkoyan K. Cinetique et facteurs associes a la reponse humorale de l’infection Cov-19, La Revue de Medecine Interne 42, A328, December  2021
6. Kalikyan Z., Harutyunyan S., Hakobyan A., Tadevosyan A., Aloyan T., Kocharyan S., Tadevosyan N. The awareness, practical approaches and attitude of healthcare providers to drug allergy in Armenia. Bratislava Medical Journal (Bratisl Lek Listy). 2022;123(4):304-310. doi: 10.4149/BLL_2022_048.
7. Movsisyan M.,Hakobyan A., Garaqyan S., Tachdjian R. The first family report of hereditary angioedema in Armenia. ALLERGY 75, 456-456, 2020
8. Movsisyan M., Hakobyan A., Tachdjian R.Treatment of Familial Mediterranean Fever decreased hereditary angioedema attacks. World Allergy Organization Journal 13 (8)
9. Movsisyan M., Fiandor A., González M., Quirce S., Bellón T., Hakobyan A., Marques-Mejias MA., Domínguez J., Cabañas R. Lymphocyte transformation test is useful in the diagnosis of fixed drug eruption induced by etoricoxib. Journal of Investigational Allergology and Clinical Immunology, J Investig Allergol Clin Immunol. 2019 Aug;29(4):307-309. doi: 10.18176/jiaci.0384.
10. Movsisyan M.R., Hakobyan A.V., Gambarov S.S. Pollen Food Allergy Syndrome (PFAS) among young Armenian adults. Journal of Allergy & Clinical Immunology, 2019; Vol. 143, Issue 2, AB433
11. Hakobyan A., Movsisyan M., Aloyan T., Zakaryan A., Gambarov S. Treating Through’’ – Clopidogrel Hypersensitivity Treatment. DHM 2018 Abstract book, p.131 (P154)
12. Movsisyan M. R., Hakobyan A. V., Hovhannisyan A. G., Gambarov. S.S. Potentially life-threatening DRESS-syndrome in a 19 year old male patient. Allergy Journal, Abstract book, 2017;72(Suppl.103);383-757, p.693
13. Hakobyan A.V., Ginosyan K.V., Malkhasyan I.E., Movsisyan M.R., Hovhannisyan A.G. Carbamazepine-induced drug reaction with eosinophilia and systemic reaction. Issues in theoretical and clinical medicine.Issues in Theoretical and Clinical Medicine, Vol 20 N 1 (111) January 2017